Key result
SGLT2 inhibitors may provide greater cardiovascular protection in highest-risk T2D patients as HHF reaches ~51% of major cardiovascular events.
Why the study?
Differentiating risk for MACE from HHF or kidney disease is important when selecting glucose-lowering therapy, prompting investigation into whether separate MACE and HHF risk scores can identify individuals more likely to benefit from GLP-1RAs versus SGLT2is.
Do GLP-1RAs or SGLT2is provide greater cardiovascular benefit in patients with type 2 diabetes stratified by TIMI Risk Scores for MACE and HHF?
Meta-Analysis
Do GLP-1RAs or SGLT2is provide greater cardiovascular benefit in patients with type 2 diabetes stratified by TIMI Risk Scores for MACE and HHF?
SGLT2 inhibitors may offer greater overall cardiovascular protection than GLP-1RAs in patients with type 2 diabetes at the highest risk for MACE, due to a disproportionate increase in heart failure risk.
Answers are grounded in this paper and cite their sources.
May support SGLT2 inhibitor preference over GLP-1RAs at highest MACE risk; extends risk-stratified data but low-certainty evidence requires validation.
OBJECTIVE: Differentiation of risk for major adverse cardiovascular events (MACE) from heart failure hospitalization (HHF) or kidney disease is important when selecting glucose-lowering therapy. We investigated the ability of separate MACE and HHF risk scores to 1) differentiate MACE from HHF risk; and 2) identify individuals more likely to benefit from either glucagon-like peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter-2 inhibitors (SGLT2is). RESEARCH DESIGN AND METHODS: We identified three trials in type 2 diabetes that reported cardiovascular outcomes stratified by Thrombolysis In Myocardial Infarction Risk Scores for MACE and HHF. Pooled placebo-arm rates of HHF, MACE, and their ratio and estimated GLP-1RA- and SGLT2i-mediated reductions in events (MACE and HHF combined) were compared across cardiovascular risk strata in the trial populations. RESULTS: The HHF rate was less frequent than MACE at all risk levels but increased from 18% of the MACE rate at low-intermediate HHF risk to 61% at highest HHF risk. Similarly, with increasing MACE risk, the incidence of HHF increased from 19% of the MACE incidence in those at low MACE risk to 51% in those with the highest MACE risk. Estimated GLP-1RA- and SGLT2i-mediated reductions in cardiovascular events were similar in those at low-intermediate MACE or HHF risk but tended to favor SGLT2is at higher risk levels of both scores. CONCLUSIONS: A greater increase in the rate of HHF relative to MACE was observed with progressively higher cardiovascular risk, regardless of the risk score applied. Consequently, SGLT2is may offer greater overall cardiovascular protection in those at highest MACE risk, not just those at highest HHF risk.
No takes yet. Share an insight, caveat, or question.
Sacre et al. (2022) conducted a meta-analysis in Type 2 diabetes. GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is) vs. Placebo was evaluated on Cardiovascular events (MACE and HHF combined) and ratio of HHF to MACE rates. SGLT2 inhibitors may offer greater overall cardiovascular protection in type 2 diabetes patients at highest major cardiovascular events risk, where HHF incidence increases to 51% of the major cardiovascular events incidence.
Synapse has enriched 10 related papers. Consider them for comparative context: